Loratadine and Diabetic nephropathy

Comparison of the effect of loratadine and placebo on urinary albumin excretion in patients with of type 2 diabetes mellitus: a double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201014049027N1

Enrollment

Registered

2021-05-14

Start date

2021-05-22

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy. Type 2 diabetes mellitus with diabetic nephropathy

Interventions

Intervention 1: Intervention group: Use loratadin 10 mg, dialy for 3 months, manufactured by Daruo-Pakhsh. Intervention 2: Control group: Use one placebo tablet dialy for 3 months manufactured at Shir

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes mellitus Albuminuria more than 30 mg/dL

Exclusion criteria

Exclusion criteria: The patients who have increased urinary protein excretion for reasons other than type 2 diabetes eGFR less than 60 ml/min/1.73m2

Design outcomes

Primary

Measure	Time frame
Microalbuminuria. Timepoint: At the beginning of the study, one month, two months and three months after starting the drug. Method of measurement: Urine test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Haghighi

Shiraz University of Medical Sciences

Alihaghighi@sums.ac.ir+98 71 3625 7914

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026